carbidopa has been researched along with Pancreatic Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bhutia, YD; Ibrahim, AF; Korac, K; Rajasekaran, D; Schniers, BK; Sniegowski, T | 1 |
| Bhutia, YD; Ganapathy, V; Gonchigar, S; Miyauchi, S; Ogura, J; Shimono, K; Yang, S | 1 |
| Addeo, P; Averous, G; Bachellier, P; Imperiale, A; Namer, IJ | 1 |
| Bachellier, P; Castinetti, F; Guillet, B; Imperiale, A; Kessler, L; Moreau, F; Mundler, O; Namer, IJ; Sebag, F; Taïeb, D; Vix, M | 1 |
| Bachellier, P; Bahougne, T; Goichot, B; Imperiale, A; Namer, IJ; Taïeb, D | 1 |
| Boisson, F; Brasse, D; Detour, J; Imperiale, A; Kessler, L; Kreutter, G; Lavaux, T; Marchand, P; Namer, IJ; Pierre, A | 1 |
| Kauhanen, S; Nuutila, P; Seppänen, M | 1 |
7 other study(ies) available for carbidopa and Pancreatic Neoplasms
| Article | Year |
|---|---|
Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth.
Topics: Animals; Carbidopa; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Kynurenine; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, Aryl Hydrocarbon; Signal Transduction; STAT Transcription Factors; Tryptophan | 2022 |
Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy.
Topics: Active Transport, Cell Nucleus; Aryl Hydrocarbon Hydroxylases; Carbidopa; Cell Nucleus; Hep G2 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Liver Neoplasms; Neoplasm Proteins; Pancreatic Neoplasms; Receptors, Aryl Hydrocarbon; Signal Transduction | 2017 |
Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on ¹⁸F-FDOPA PET/CT.
Topics: Adult; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radioisotopes; Humans; Male; Multimodal Imaging; Neuroendocrine Tumors; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Premedication; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
18F-FDOPA PET/CT imaging of insulinoma revisited.
Topics: Adult; Aged; Aged, 80 and over; Carbidopa; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism; Insulinoma; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Premedication; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.
Topics: Adult; Carbidopa; Dihydroxyphenylalanine; Female; Humans; Hyperinsulinism; Hypoglycemia; Insulinoma; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Premedication; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Effect of Carbidopa on 18F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging.
Topics: Animals; Carbidopa; Cell Line, Tumor; Dihydroxyphenylalanine; Female; Image Enhancement; Insulinoma; Metabolic Clearance Rate; Mice, Nude; Organ Specificity; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Tissue Distribution | 2017 |
Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography.
Topics: Carbidopa; Diagnostic Errors; Dihydroxyphenylalanine; Enzyme Inhibitors; Fluorine Radioisotopes; Humans; Hyperplasia; Insulin-Secreting Cells; Insulinoma; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Premedication; Radiopharmaceuticals | 2008 |